Ponatinib was approved as a second‐line treatment for patients with Ph+ acute lymphoblastic leukaemia (ALL) and chronic myeloid leukaemia (CML) as a BCR‐ABL inhibitor, with a particular focus on addressing the ABL‐T1351 mutation [14, 15]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.